Hypertension, Stroke
Conditions
Brief summary
This study will assess the comparative effectiveness, cost-effectiveness and sustainability of two telemonitoring interventions in reducing blood pressure and recurrent stroke among 450 high-risk Black and Hispanic stroke patients. The primary hypothesis is that home blood pressure telemonitoring supplemented with individualized, culturally tailored telephone-based nurse case management will have greater effects on blood pressure reduction and stroke recurrence and, while it will be more costly, it will also be more cost-effective than home blood pressure telemonitoring alone. Results of this study will provide strong empirical evidence to inform clinical guidelines and practice, which may lead to reductions in stroke disparities in the United States.
Interventions
BEHAVIORALHome BP Telemonitoring (HBPTM)
Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
BEHAVIORALNurse Case Management (NCM)
Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS)
NYU Langone Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Black or Hispanic * Age 18 years or older * English or Spanish speaking * Patients who have had an ischemic or hemorrhagic stroke * Modified Rankin scale score of ≤ 3 * Average screening SBP ≥ 140 mm Hg from three BP readings taken at two separate visits with a validated automated device * Receiving care at the study site for at least 6 months and planning to continue receiving care at the site for the next two years.
Exclusion criteria
* Being deemed unable to comply with the study protocol (either self-selected or by indicating during screening that he/she could not complete all requested tasks including using the HBPTM or interacting with the NCM if he/she were to be randomized to the intervention group) * Participation in other clinical trials * Diagnosis of cognitive dysfunction or significant psychiatric comorbidity (as indicated in medical record) * Patients with upper arm circumference ≥ 52 cm, the maximum limit of the extra-large BP cuff * Diagnosis of dialysis or end stage renal disease * Relocating out of area or extended travel during study period * Significant verbal speech impairment; unable to participate in intervention telephone sessions * Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 12-month systolic blood pressure (SBP) change | Baseline, 12 months |
Secondary
| Measure | Time frame |
|---|---|
| 24-month stroke recurrence | 24 months |
| Cost-effectiveness for reducing SBP at 12 months | 12 months |
| Cost-effectiveness for reducing stroke recurrence at 24 months | 24 Months |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in health behaviors | 6, 12, 24 months | diet, physical activity, medication adherence, weight loss |
| Antihypertensive medication intensification | 6, 12, 24 months | adding, changing dose, or changing class of medications |
| Change in other stroke risk factors | 6, 12, 24 months | lipids, blood glucose |
Countries
United States
Outcome results
None listed